An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Expanded access is currently available for this treatment.
Verified July 2014 by Eisai Inc.
Information provided by (Responsible Party):
First received: October 1, 2010
Last updated: July 25, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||Expanded access is currently available for this treatment.|
|Estimated Study Completion Date:||March 2015|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|